Summary of AEs in patients with previously untreated FL (N = 40)
| . | Induction phase n (%) . | Maintenance phase n (%) . | Follow-up phase n (%) . | Overall n (%) . |
|---|---|---|---|---|
| Patients with any AE | 40 (100.0) | 37 (92.5) | 14 (35.0) | 40 (100.0) |
| Grade 3-5 AE | 21 (52.5) | 24 (60.0) | 9 (22.5) | 32 (80.0) |
| Grade 5 AE | 1 (2.5) | 1 (2.5) | 3 (7.5) | 5 (12.5)∗ |
| SAE | 9 (22.5) | 12 (30.0) | 6 (15.0) | 18 (45.0) |
| SAE related to atezo | 3 (7.5) | 4 (10.0) | 3 (7.5) | 8 (20.0) |
| SAE related to G | 2 (5.0) | 5 (12.5) | 2 (5.0) | 8 (20.0) |
| SAE related to bendamustine | 2 (5.0) | 1 (2.5) | 0 (0.0) | 3 (7.5) |
| AE leading to any study treatment discontinuation | 4 (10.0) | 13 (32.5) | 2 (5.0) | 19 (47.5) |
| AESI related to atezolizumab | 12 (30.0) | 15 (37.5) | 3 (7.5) | 20 (50.0) |
| . | Induction phase n (%) . | Maintenance phase n (%) . | Follow-up phase n (%) . | Overall n (%) . |
|---|---|---|---|---|
| Patients with any AE | 40 (100.0) | 37 (92.5) | 14 (35.0) | 40 (100.0) |
| Grade 3-5 AE | 21 (52.5) | 24 (60.0) | 9 (22.5) | 32 (80.0) |
| Grade 5 AE | 1 (2.5) | 1 (2.5) | 3 (7.5) | 5 (12.5)∗ |
| SAE | 9 (22.5) | 12 (30.0) | 6 (15.0) | 18 (45.0) |
| SAE related to atezo | 3 (7.5) | 4 (10.0) | 3 (7.5) | 8 (20.0) |
| SAE related to G | 2 (5.0) | 5 (12.5) | 2 (5.0) | 8 (20.0) |
| SAE related to bendamustine | 2 (5.0) | 1 (2.5) | 0 (0.0) | 3 (7.5) |
| AE leading to any study treatment discontinuation | 4 (10.0) | 13 (32.5) | 2 (5.0) | 19 (47.5) |
| AESI related to atezolizumab | 12 (30.0) | 15 (37.5) | 3 (7.5) | 20 (50.0) |
atezo, atezolizumab; G, obinutuzumab.
Included Pneumocystis pneumonia (n = 1), sudden death (n = 1), cardiac arrest (n = 1), adenocarcinoma (n = 1), and progressive multifocal leukoencephalopathy (n = 1). The case of Pneumocystis pneumonia was considered to be possibly related to the use of prednisone used to treat elevated lipase (atezo-related) in the same patient.